HRP20160988T1 - Farmaceutski sastavi s dvostrukim djelovanjem na temelju superstruktura od antagonista/blokatora receptora angiotenzina (arb) i neutralnih inhibitora endopeptidaze (nep) - Google Patents
Farmaceutski sastavi s dvostrukim djelovanjem na temelju superstruktura od antagonista/blokatora receptora angiotenzina (arb) i neutralnih inhibitora endopeptidaze (nep) Download PDFInfo
- Publication number
- HRP20160988T1 HRP20160988T1 HRP20160988TT HRP20160988T HRP20160988T1 HR P20160988 T1 HRP20160988 T1 HR P20160988T1 HR P20160988T T HRP20160988T T HR P20160988TT HR P20160988 T HRP20160988 T HR P20160988T HR P20160988 T1 HRP20160988 T1 HR P20160988T1
- Authority
- HR
- Croatia
- Prior art keywords
- dosage form
- oral dosage
- solid oral
- biphenyl
- ylmethyl
- Prior art date
Links
- 102000003729 Neprilysin Human genes 0.000 title 1
- 108090000028 Neprilysin Proteins 0.000 title 1
- 229940127282 angiotensin receptor antagonist Drugs 0.000 title 1
- 229940125364 angiotensin receptor blocker Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000463 material Substances 0.000 claims 8
- 239000006186 oral dosage form Substances 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- 239000007787 solid Substances 0.000 claims 7
- 238000002156 mixing Methods 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000003826 tablet Substances 0.000 claims 3
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 238000005056 compaction Methods 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 230000006835 compression Effects 0.000 claims 1
- 239000007941 film coated tablet Substances 0.000 claims 1
- 239000007888 film coating Substances 0.000 claims 1
- 238000009501 film coating Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000000227 grinding Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000003825 pressing Methods 0.000 claims 1
- PYNXFZCZUAOOQC-UTKZUKDTSA-N sacubitril Chemical compound C1=CC(C[C@H](C[C@@H](C)C(=O)OCC)NC(=O)CCC(O)=O)=CC=C1C1=CC=CC=C1 PYNXFZCZUAOOQC-UTKZUKDTSA-N 0.000 claims 1
- 238000007873 sieving Methods 0.000 claims 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 1
- 229960004699 valsartan Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (5)
1. Čvrsti oralni dozni oblik, naznačen time, da obuhvaća sljedeće:
spoj trinatrij-[3-((1S,3R)-1-bifenil-4-ilmetil-3-etoksikarbonil-1-butilkarbamoil)-propionat-(S)-3'-metil-2'-(pentanoil{2''-(tetrazol-5-ilat)bifenil-4'-ilmetil}amino)butirat]hemipentahidrata u koncentraciji od 4 % do 90 % po masi sastava; i
najmanje jedno farmaceutski prihvatljivo pomoćno sredstvo,
pri čemu je spoj prisutan u doznoj jačini od 100, 200 ili 400 mg u odnosu prema odgovarajućoj kombiniranoj količini kiseline bez valsartana i (2R,4S)-5-bifenil-4-il-4-(3-karboksi-propionilamino)-2-metil-pentanska kiselina-etil-estera u omjeru 1:1 po jediničnom doznom obliku, te time, da čvrsti oralni dozni oblik je tableta sabijena pomoću valjaka.
2. Čvrsti oralni dozni oblik prema zahtjevu 1, naznačen time, da spomenuta tableta je formulacija s brzim oslobađanjem.
3. Postupak priprave čvrstog oralnog doznog oblika prema zahtjevu 1, naznačen time, da obuhvaća sljedeće korake:
miješanje trinatrij-[3-((1S,3R)-1-bifenil-4-ilmetil-3-etoksikarbonil-1-butilkarbamoil)-propionat-(S)-3'-metil-2'-(pentanoil{2''-(tetrazol-5-ilat)bifenil-4'-ilmetil}amino)butirat]hemipentahidrata s najmanje jednim farmaceutski prihvatljivim pomoćnim sredstvom u svrhu tvorbe smjese;
sabijanje navedene smjese pomoću tlačenja valjcima;
opcijski miješanje s dodatnim farmaceutski prihvatljivim pomoćnim sredstvima; i
stlačivanje konačne smjese u čvrsti oralni dozni oblik.
4. Postupak proizvodnje čvrstog oralnog doznog oblika prema zahtjevu 1, naznačen time, da obuhvaća sljedeće korake:
prosijavanje spoja i farmaceutskih prihvatljivih pomoćnih sredstava za tvorbu prosijanog materijala;
miješanje prosijanog materijala za tvorbu pomiješanog materijala;
sabijanje pomiješanog materijala valjcima za tvorbu sabijenog materijala;
mljevenje sabijenog materijala za tvorbu mljevenog materijala;
opcijski miješanje mljevenog materijala s dodatnim farmaceutski prihvatljivim pomoćnim sredstvima za tvorbu konačne smjese;
stlačivanje konačne smjese za tvorbu tablete;
opcijski nanošenje film-obloge, kako bi se dobile filmom obložene tablete.
5. Čvrsti oralni dozni oblik prema zahtjevu 1, naznačen time, da oralni dozni oblik omogućava brzinu resorpcije kiseline bez valsartana, koja iznosi tmax od 1 do 2,2 sata nakon davanja jednostruke doze navedenog doznog oblika.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98566807P | 2007-11-06 | 2007-11-06 | |
| EP10173506.6A EP2295035B1 (en) | 2007-11-06 | 2008-11-04 | Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160988T1 true HRP20160988T1 (hr) | 2016-10-07 |
Family
ID=40451030
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230178TT HRP20230178T3 (hr) | 2007-11-06 | 2008-11-04 | Farmaceutski pripravci temeljeni na nadgradnjama antagonista/blokatora angiotenzinskog receptora (arb) i inhibitoru neutralne endopeptidaze (nep) |
| HRP20150459TT HRP20150459T1 (hr) | 2007-11-06 | 2008-11-04 | Farmaceutski pripravci na bazi superstruktura antagonista/blokatora angiontenzinskih receptora (arb) i inhibitora neutralne endopeptidaze (nep) |
| HRP20160988TT HRP20160988T1 (hr) | 2007-11-06 | 2016-08-02 | Farmaceutski sastavi s dvostrukim djelovanjem na temelju superstruktura od antagonista/blokatora receptora angiotenzina (arb) i neutralnih inhibitora endopeptidaze (nep) |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230178TT HRP20230178T3 (hr) | 2007-11-06 | 2008-11-04 | Farmaceutski pripravci temeljeni na nadgradnjama antagonista/blokatora angiotenzinskog receptora (arb) i inhibitoru neutralne endopeptidaze (nep) |
| HRP20150459TT HRP20150459T1 (hr) | 2007-11-06 | 2008-11-04 | Farmaceutski pripravci na bazi superstruktura antagonista/blokatora angiontenzinskih receptora (arb) i inhibitora neutralne endopeptidaze (nep) |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US20100267786A1 (hr) |
| EP (4) | EP3067043B1 (hr) |
| JP (2) | JP5653218B2 (hr) |
| KR (2) | KR101700062B1 (hr) |
| CN (2) | CN101848700A (hr) |
| AR (1) | AR069184A1 (hr) |
| AU (1) | AU2008324878B2 (hr) |
| BR (1) | BRPI0823505A2 (hr) |
| CA (1) | CA2703598C (hr) |
| CL (1) | CL2008003298A1 (hr) |
| CY (2) | CY1116280T1 (hr) |
| DK (3) | DK3067043T3 (hr) |
| EC (1) | ECSP10010160A (hr) |
| ES (3) | ES2587336T3 (hr) |
| FI (1) | FI3067043T3 (hr) |
| GT (1) | GT201000131A (hr) |
| HR (3) | HRP20230178T3 (hr) |
| HU (2) | HUE028866T2 (hr) |
| IL (3) | IL262990B2 (hr) |
| JO (1) | JOP20080499B1 (hr) |
| MA (1) | MA31797B1 (hr) |
| MX (1) | MX2010004930A (hr) |
| MY (1) | MY153730A (hr) |
| NZ (1) | NZ584686A (hr) |
| PE (2) | PE20091390A1 (hr) |
| PL (3) | PL2217205T3 (hr) |
| PT (3) | PT2295035T (hr) |
| RU (1) | RU2493844C3 (hr) |
| SG (1) | SG185951A1 (hr) |
| SI (3) | SI2295035T1 (hr) |
| TN (1) | TN2010000200A1 (hr) |
| TW (1) | TWI484982B (hr) |
| WO (1) | WO2009061713A1 (hr) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101700062B1 (ko) | 2007-11-06 | 2017-01-26 | 노파르티스 아게 | 안지오텐신 수용체 길항제/차단제 （ａｒｂ） 및 중성 엔도펩티다제 （ｎｅｐ） 억제제의 초구조에 기초한 이중-작용 제약 조성물 |
| DK2435409T3 (da) | 2009-05-28 | 2014-10-27 | Novartis Ag | Substituerede aminopropionsyrederivater som neprilysininhibitorer |
| EP3048100A1 (en) | 2009-05-28 | 2016-07-27 | Novartis AG | Substituted aminobutyric derivatives as neprilysin inhibitors |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
| MX341174B (es) | 2010-08-24 | 2016-08-10 | Novartis Ag * | Tratamiento de hipertension y/o prevencion o tratamiento de insuficiencia cardiaca en un mamifero que recibe terapia anti-coagulante. |
| US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| KR20200111822A (ko) | 2012-08-24 | 2020-09-29 | 노파르티스 아게 | 심방 확장 또는 재형성을 특징으로 하는 질환을 치료하기 위한 nep 억제제 |
| RS57358B1 (sr) | 2013-02-14 | 2018-08-31 | Novartis Ag | Supstituisani derivati bisfenilbutanoil fosfonske kiseline kao inhibitori nep (neutralne endopeptidaze) |
| US9102635B2 (en) | 2013-02-14 | 2015-08-11 | Novartis Ag | Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy |
| ES2767084T3 (es) | 2013-08-26 | 2020-06-16 | Novartis Ag | Nuevo uso |
| JP2016530282A (ja) * | 2013-08-26 | 2016-09-29 | ノバルティス アーゲー | 新規使用 |
| CN106795099B (zh) * | 2014-04-10 | 2019-11-26 | 南京奥昭生物科技有限公司 | 用于治疗高血压和心血管疾病的前药和组合物 |
| CN105461647B (zh) * | 2014-09-28 | 2018-06-29 | 四川海思科制药有限公司 | 缬沙坦沙库比曲三钠盐复合物的固态形式及其制备方法和用途 |
| CN110922366B (zh) | 2014-12-08 | 2023-02-03 | 苏州晶云药物科技股份有限公司 | 一种包含缬沙坦和ahu377的三钠盐超分子复合物的新晶型及其制备方法 |
| CN104473938B (zh) * | 2014-12-30 | 2017-06-09 | 北京瑞都医药科技有限公司 | 一种治疗慢性心衰药物及其制备方法 |
| CN104826115A (zh) * | 2015-04-19 | 2015-08-12 | 浙江巨泰药业有限公司 | 一种抗心衰药物组合物及其制备方法 |
| JP6576469B2 (ja) | 2015-05-11 | 2019-09-18 | ノバルティス アーゲー | 心不全の治療のためのサクビトリル−バルサルタンの用量計画 |
| WO2016193883A1 (en) | 2015-05-29 | 2016-12-08 | Novartis Ag | Sacubitril and valsartan for treating metabolic disease |
| CN106309388A (zh) * | 2015-06-30 | 2017-01-11 | 深圳信立泰药业股份有限公司 | 一种用于心衰治疗的药物组合物及其制备方法 |
| WO2017006254A1 (en) | 2015-07-08 | 2017-01-12 | Novartis Ag | Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist |
| CN106074421A (zh) * | 2015-07-11 | 2016-11-09 | 凌莉 | 一种提高稳定性的药物组合物 |
| CN105997994A (zh) * | 2015-07-11 | 2016-10-12 | 凌莉 | 一种固体口服型制剂及其制备方法 |
| CN106176724A (zh) * | 2015-07-11 | 2016-12-07 | 凌莉 | 一种稳定的固体药物组合物及其制备方法 |
| CN106176723A (zh) * | 2015-07-11 | 2016-12-07 | 凌莉 | 一种固体药物组合物及其制备方法 |
| CN105997993B (zh) * | 2015-07-11 | 2018-03-30 | 麦丽芳 | 一种用于心血管疾病治疗的固体口服型制剂及其制备方法 |
| CN106176725A (zh) * | 2015-07-11 | 2016-12-07 | 凌莉 | 一种提高稳定性的药物组合物及其制备方法和用途 |
| WO2017012600A1 (en) | 2015-07-20 | 2017-01-26 | Zentiva, K.S. | A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof |
| CN106397248A (zh) * | 2015-08-03 | 2017-02-15 | 深圳信立泰药业股份有限公司 | 一种lcz696结晶粉末及其制备方法 |
| EP3355880A1 (en) | 2015-08-28 | 2018-08-08 | Novartis AG | New use |
| WO2017037596A1 (en) * | 2015-08-28 | 2017-03-09 | Dr. Reddy's Laboratories Limited | Amorphous solid dispersion of lcz-696 |
| US20180303799A1 (en) * | 2015-10-16 | 2018-10-25 | Shenzhen Salubris Pharmaceuticals Co., Ltd | An Oral Preparation for the Treatment of Cardiovascular Disease and Its Preparation Method |
| CN105669581B (zh) * | 2015-11-09 | 2017-03-22 | 成都苑东生物制药股份有限公司 | 一种血管紧张受体拮抗剂和中性内肽酶抑制剂复合物 |
| WO2017085573A1 (en) * | 2015-11-20 | 2017-05-26 | Lupin Limited | Amorphous sacubitril-valsartan complex and process for preparation thereof |
| CN105330609B (zh) * | 2015-12-07 | 2017-12-22 | 南京正大天晴制药有限公司 | 一种制备lcz696的方法 |
| CN105935358B (zh) * | 2015-12-18 | 2019-06-07 | 重庆两江药物研发中心有限公司 | 一种沙库比曲缬沙坦缓释剂及其制备方法 |
| CN105929031B (zh) * | 2015-12-18 | 2018-08-21 | 重庆两江药物研发中心有限公司 | 一种血管紧张素受体拮抗剂和nep抑制剂的复合物中杂质的分离方法 |
| CN106905253B (zh) * | 2015-12-23 | 2020-01-03 | 正大天晴药业集团股份有限公司 | 一种超分子复合物的结晶 |
| CN108601741B (zh) * | 2016-02-03 | 2022-05-24 | 诺华股份有限公司 | 有机化合物的盖伦制剂 |
| HK1256865A1 (zh) | 2016-02-03 | 2019-10-04 | Novartis Ag | 有机化合物的盖伦制剂 |
| CN105748420B (zh) * | 2016-03-04 | 2018-11-06 | 山东省药学科学院 | 一种治疗心力衰竭的lcz696缓释骨架片的制备方法 |
| CN105902506A (zh) * | 2016-06-12 | 2016-08-31 | 佛山市腾瑞医药科技有限公司 | 一种沙卡布曲缬沙坦制剂及其应用 |
| WO2018069937A1 (en) | 2016-10-13 | 2018-04-19 | Mylan Laboratories Limited | Solid dispersions of trisodium sacubitril valsartan and process for the preparation thereof |
| US20210085610A1 (en) * | 2017-03-31 | 2021-03-25 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Stable hot-melt extrudate containing valsartan and sacubitril |
| WO2018178295A1 (en) | 2017-03-31 | 2018-10-04 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Stable hot-melt extrudate containing valsartan and sacubitril |
| WO2018211479A1 (en) * | 2017-05-19 | 2018-11-22 | Lupin Limited | Stabilized compositions of angiotensin ii inhibitors and neutral endopeptidase inhibitors and process for preparation thereof |
| WO2019008485A1 (en) * | 2017-07-06 | 2019-01-10 | Mankind Pharma Ltd | FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL |
| EA202090398A1 (ru) | 2017-07-28 | 2020-05-15 | Синтон Б.В. | Фармацевтическая композиция, включающая сакубитрил и валсартан |
| EP3694493A1 (en) | 2017-10-13 | 2020-08-19 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Tablet containing valsartan and sacubitril |
| WO2019180735A1 (en) * | 2018-03-19 | 2019-09-26 | Natco Pharma Limited | Stable pharmaceutical compositions comprising sacubitril-valsartan complex |
| WO2019246503A1 (en) | 2018-06-22 | 2019-12-26 | Ideaz, Llc | Diphenyl tablets and methods of preparing the same |
| EP3840746A1 (en) | 2018-08-23 | 2021-06-30 | Novartis AG | New pharmaceutical use for the treatment of heart failure |
| WO2020039394A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | New drug combinations |
| EP3766484B1 (en) | 2019-07-19 | 2021-08-25 | Zentiva, K.S. | Solid pharmaceutical dosage form comprising valsartan and sacubitril |
| KR102545274B1 (ko) | 2020-02-26 | 2023-06-20 | 에리슨제약(주) | 사쿠비트릴 및 발사르탄을 포함하는 심부전 치료용 서방성 제제, 및 이를 포함하는 다중방출 복합제제와 이의 제조방법 |
| KR20210120560A (ko) | 2020-03-27 | 2021-10-07 | 주식회사 유영제약 | 고함량의 주성분을 포함하는 정제 및 그 제조방법 |
| KR20210138510A (ko) | 2020-05-12 | 2021-11-19 | 에리슨제약(주) | 사쿠비트릴, 발사르탄 및 네비보롤을 포함하는 심부전 및 허혈성 심질환의 예방 또는 치료용 약제학적 조성물 및 이를 포함하는 약제학적 복합제제 |
| KR20220091767A (ko) | 2020-12-24 | 2022-07-01 | 주식회사 보령 | 사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물 |
| KR102486815B1 (ko) | 2021-01-20 | 2023-01-10 | 주식회사 대웅제약 | Nep 저해제 및 arb를 포함하는 약학 조성물 및 이의 제조 방법 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US608220A (en) | 1898-08-02 | Mechanical movement | ||
| US607893A (en) | 1898-07-26 | Automatic switch-operating machine | ||
| US607355A (en) | 1898-07-12 | Carrier for bicycles | ||
| US735093A (en) | 1903-01-31 | 1903-08-04 | Oscar Greenwald | Elevator-cable guard. |
| GB9613470D0 (en) * | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| BR9814877A (pt) * | 1997-11-17 | 2000-10-03 | Smithkline Beecham Corp | Formulações de dosagem oral de elevada carga medicamentosa de liberação imediata e modificada e processos para sua fabricação |
| US6558699B2 (en) * | 1997-11-17 | 2003-05-06 | Smithkline Beecham Corporation | High drug load immediate and modified release oral dosage formulations and processes for their manufacture |
| EP1087775B1 (en) * | 1998-06-17 | 2005-08-17 | Bristol-Myers Squibb Company | Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination |
| BR9916576A (pt) * | 1998-12-23 | 2001-10-02 | Novartis Ag | Uso de antagonista receptor at-1 ou modulador receptor at-2 para o tratamento de doenças associadas com um aumento de receptores at-1 ou at-2 |
| NZ523557A (en) | 2000-07-19 | 2004-12-24 | Novartis Ag | Calcium salt of valsartan |
| US7468390B2 (en) * | 2002-01-17 | 2008-12-23 | Novartis Ag | Methods of treatment and pharmaceutical composition |
| PL212318B1 (pl) * | 2002-01-17 | 2012-09-28 | Novartis Ag | Kompozycja farmaceutyczna zawierajaca walsartan oraz inhibitor obojetnej endopeptydazy (NEP) oraz zestaw zawierajacy te kompozycje |
| JP3751287B2 (ja) * | 2002-03-27 | 2006-03-01 | バイエル薬品株式会社 | 小型化されたニフェジピン有核錠剤 |
| AU2003223637A1 (en) | 2002-04-15 | 2003-11-03 | Dr. Reddy's Laboratories Limited | Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- (2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl) amine (valsartan) |
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| EP1511739B1 (en) | 2003-03-17 | 2008-04-30 | Teva Pharmaceutical Industries Ltd. | Polymorphs of valsartan |
| WO2005014043A1 (en) | 2003-07-16 | 2005-02-17 | Boehringer Ingelheim International Gmbh | Chlorthalidone combinations |
| GB0402262D0 (en) * | 2004-02-02 | 2004-03-10 | Novartis Ag | Process for the manufacture of organic compounds |
| GT200600371A (es) | 2005-08-17 | 2007-03-21 | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas | |
| US20090304755A1 (en) * | 2005-10-27 | 2009-12-10 | Raghu Rami Reddy Kasu | Pharmaceutical formulation of losartan |
| WO2007052307A2 (en) | 2005-10-31 | 2007-05-10 | Lupin Limited | Stable solid oral dosage forms of valsartan |
| WO2007056342A2 (en) | 2005-11-07 | 2007-05-18 | Stryker Corporation | Patient handling device including local status indication, one-touch fowler angle adjustment, and power-on alarm configuration |
| CN101300030A (zh) | 2005-11-08 | 2008-11-05 | 诺瓦提斯公司 | 血管紧张素ⅱ受体阻滞剂、钙通道阻滞剂和另一活性物质的组合产品 |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| EP1897537A1 (en) * | 2006-09-04 | 2008-03-12 | Novartis AG | Composition comprising an angiotensin II receptor antagonist |
| KR101700062B1 (ko) | 2007-11-06 | 2017-01-26 | 노파르티스 아게 | 안지오텐신 수용체 길항제/차단제 （ａｒｂ） 및 중성 엔도펩티다제 （ｎｅｐ） 억제제의 초구조에 기초한 이중-작용 제약 조성물 |
-
2008
- 2008-11-04 KR KR1020157033633A patent/KR101700062B1/ko not_active Ceased
- 2008-11-04 SI SI200831654A patent/SI2295035T1/sl unknown
- 2008-11-04 ES ES10173506.6T patent/ES2587336T3/es active Active
- 2008-11-04 HR HRP20230178TT patent/HRP20230178T3/hr unknown
- 2008-11-04 SG SG2012081394A patent/SG185951A1/en unknown
- 2008-11-04 ES ES08848154.4T patent/ES2536514T3/es active Active
- 2008-11-04 NZ NZ584686A patent/NZ584686A/xx unknown
- 2008-11-04 DK DK16157767.1T patent/DK3067043T3/da active
- 2008-11-04 IL IL262990A patent/IL262990B2/en unknown
- 2008-11-04 CN CN200880114940A patent/CN101848700A/zh active Pending
- 2008-11-04 SI SI200832204T patent/SI3067043T1/sl unknown
- 2008-11-04 MY MYPI2010001722A patent/MY153730A/en unknown
- 2008-11-04 PL PL08848154T patent/PL2217205T3/pl unknown
- 2008-11-04 EP EP16157767.1A patent/EP3067043B1/en active Active
- 2008-11-04 JP JP2010533185A patent/JP5653218B2/ja active Active
- 2008-11-04 CN CN2013101540642A patent/CN103251587A/zh active Pending
- 2008-11-04 SI SI200831427T patent/SI2217205T1/sl unknown
- 2008-11-04 JO JOP/2008/0499A patent/JOP20080499B1/ar active
- 2008-11-04 AU AU2008324878A patent/AU2008324878B2/en active Active
- 2008-11-04 RU RU2010123027A patent/RU2493844C3/ru active
- 2008-11-04 FI FIEP16157767.1T patent/FI3067043T3/fi active
- 2008-11-04 MX MX2010004930A patent/MX2010004930A/es active IP Right Grant
- 2008-11-04 EP EP22200982.1A patent/EP4186491A1/en active Pending
- 2008-11-04 CA CA2703598A patent/CA2703598C/en active Active
- 2008-11-04 PE PE2008001886A patent/PE20091390A1/es not_active Application Discontinuation
- 2008-11-04 PL PL16157767.1T patent/PL3067043T3/pl unknown
- 2008-11-04 PL PL10173506.6T patent/PL2295035T3/pl unknown
- 2008-11-04 KR KR1020107009852A patent/KR101589317B1/ko not_active Ceased
- 2008-11-04 HU HUE10173506A patent/HUE028866T2/en unknown
- 2008-11-04 DK DK08848154.4T patent/DK2217205T3/en active
- 2008-11-04 WO PCT/US2008/082324 patent/WO2009061713A1/en active Application Filing
- 2008-11-04 PT PT101735066T patent/PT2295035T/pt unknown
- 2008-11-04 ES ES16157767T patent/ES2939163T3/es active Active
- 2008-11-04 PE PE2013002393A patent/PE20141072A1/es active IP Right Grant
- 2008-11-04 HR HRP20150459TT patent/HRP20150459T1/hr unknown
- 2008-11-04 EP EP10173506.6A patent/EP2295035B1/en not_active Revoked
- 2008-11-04 HU HUE16157767A patent/HUE061321T2/hu unknown
- 2008-11-04 EP EP08848154.4A patent/EP2217205B1/en not_active Revoked
- 2008-11-04 PT PT88481544T patent/PT2217205E/pt unknown
- 2008-11-04 AR ARP080104826A patent/AR069184A1/es not_active Application Discontinuation
- 2008-11-04 US US12/741,251 patent/US20100267786A1/en not_active Abandoned
- 2008-11-04 DK DK10173506.6T patent/DK2295035T3/en active
- 2008-11-04 PT PT161577671T patent/PT3067043T/pt unknown
- 2008-11-04 BR BRPI0823505-8A patent/BRPI0823505A2/pt not_active Application Discontinuation
- 2008-11-05 CL CL2008003298A patent/CL2008003298A1/es unknown
- 2008-11-05 TW TW097142724A patent/TWI484982B/zh active
-
2010
- 2010-04-19 IL IL205208A patent/IL205208A/en active IP Right Grant
- 2010-04-30 MA MA32803A patent/MA31797B1/fr unknown
- 2010-04-30 TN TN2010000200A patent/TN2010000200A1/fr unknown
- 2010-05-05 GT GT201000131A patent/GT201000131A/es unknown
- 2010-05-06 EC EC2010010160A patent/ECSP10010160A/es unknown
-
2014
- 2014-08-12 JP JP2014164022A patent/JP2015038069A/ja not_active Withdrawn
-
2015
- 2015-05-14 CY CY20151100426T patent/CY1116280T1/el unknown
-
2016
- 2016-08-02 HR HRP20160988TT patent/HRP20160988T1/hr unknown
- 2016-08-08 CY CY20161100778T patent/CY1117883T1/el unknown
-
2017
- 2017-01-03 IL IL249922A patent/IL249922A0/en unknown
-
2020
- 2020-12-02 US US17/109,716 patent/US20210085631A1/en not_active Abandoned
-
2023
- 2023-05-09 US US18/314,745 patent/US20240115536A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160988T1 (hr) | Farmaceutski sastavi s dvostrukim djelovanjem na temelju superstruktura od antagonista/blokatora receptora angiotenzina (arb) i neutralnih inhibitora endopeptidaze (nep) | |
| KR101259645B1 (ko) | 직접 압축 제제 및 방법 | |
| TWI476191B (zh) | 包含伊貝沙坦（ｉｒｂｅｓａｒｔａｎ）及阿洛地平（ａｍｌｏｄｉｐｉｎｅ）之固體醫藥固定劑量組合物，其製備及其治療應用 | |
| CN103002883B (zh) | 包含HMG-CoA还原酶抑制剂和厄贝沙坦的双层片剂形式的药物制剂 | |
| KR20160058763A (ko) | 암로디핀 및 발사르탄를 함유하는 안정적인 약제학적 조성물 | |
| WO2001087284A3 (en) | Aldosterone antagonist composition for release during aldosterone acrophase | |
| CN101897676B (zh) | 一种替米沙坦片剂组合物 | |
| KR101788350B1 (ko) | 아카보스를 함유하는 경구 붕해 정제 | |
| EP2197428B1 (en) | Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof | |
| EP1994926B9 (en) | Valsartan formulations | |
| CA2761212A1 (en) | Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of it manufacturing | |
| CN101219120A (zh) | 替米沙坦分散片及其制备方法 | |
| RU2015106688A (ru) | Препараты и способы получения препаратов для применения при опорожнении толстой кишки | |
| EP3793529A1 (en) | Stable pharmaceutical compositions of dpp-iv inhibitors in combination with metformin in the form of immediate release tablets | |
| ES2573708T3 (es) | Comprimido dispersable por vía oral que contiene base de sildenafilo compactada | |
| RU2008147668A (ru) | Способ получения фармацевтических композиций посредством прессования нагреваемыми роликами | |
| US20070202164A1 (en) | Andrographis Extract Formulations | |
| CN102697778A (zh) | 缬沙坦氨氯地平复方固体制剂及其制备方法 | |
| WO2020098904A1 (en) | Dosage form containing metformin and a dipeptidyl peptidase iv inhibitor | |
| Singh et al. | Design and characterization of sustained release matrix tablets of metformin hydrochloride using combination of hydrophilic polymers | |
| KR101243747B1 (ko) | 고함량 리세드론산 함유 골다공증 치료용 약학조성물 | |
| NZ628603A (en) | Sodium ibuprofen tablets and methods of manufacturing pharmaceutical compositions including sodium ibuprofen | |
| CN100508977C (zh) | 美托法宗缓释片 | |
| RU2010129544A (ru) | Фармацевтическая композиция | |
| EP3244880A1 (en) | A stable bilayer pharmaceutical tablet compositions comprising fixed dose of irbesartan and amlodipine |